Zobrazeno 1 - 10
of 13
pro vyhledávání: '"C. H. Spiridonidis"'
Autor:
Holly E. Laufman, Douglas Reader, Heather Meek, Leslie R. Laufman, C. H. Spiridonidis, Sanjay Yadav
Publikováno v:
Community Oncology. 4:561-563
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a50029d581f3bb16f899bb2943a59a85
https://doi.org/10.1016/s1548-5315(11)70034-1
https://doi.org/10.1016/s1548-5315(11)70034-1
Autor:
Alan Sandler, Rafat Ansari, Frank Monaco, Craig R. Nichols, Charles D. Blanke, M. A. Carey, B. Fisher, Lawrence H. Einhorn, C. H. Spiridonidis
Publikováno v:
American Journal of Clinical Oncology. 21:294-297
This phase II trial investigated the activity and toxicity of CODE (cisplatin, vincristine, doxorubicin, etoposide) chemotherapy with the addition of granulocyte colony-stimulating factor (G-CSF) in patients who had chemotherapy-naive, advanced, or m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195f115a0aef59240541d55555049f15
https://doi.org/10.1097/00000421-199806000-00019
https://doi.org/10.1097/00000421-199806000-00019
Autor:
Joanne E. Mortimer, Patrick J. Loehrer, René Gonin, Kathy D. Miller, William Pletcher, C. H. Spiridonidis, George Weber, Rafat Ansari, John McClean
Publikováno v:
Investigational New Drugs. 14:207-212
From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated with weekly oral methotrexate (7.5 mg/M2 every 6 hours for 6 doses) and continuous oral AZT (200 mg four times daily). Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebb20d05329835d91e4790f48883fda3
https://doi.org/10.1007/bf00210792
https://doi.org/10.1007/bf00210792
Publikováno v:
Annals of Oncology. 10:989-991
Summary Purpose To evaluate the efficacy of a novel multiday schedule of vinorelbine and cisplatin in patients with advanced NSCLC. Patients and methods Thirty patients were enrolled, including 27 patients with stage IV disease, and 11 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63e5a1c678014ca47f74d8a78fb8df38
https://doi.org/10.1023/a:1008355504913
https://doi.org/10.1023/a:1008355504913
Autor:
J. Pritchard, T. Patel, T. Moore, L. R. Laufman, J. Jones, D. Colborn, J. Zangmeister, C. H. Spiridonidis, J. P. Kuebler, N. Larrimer, L. Carman, R. Roach, L. Gutterman, M. Segal
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(9)
sColumbus Community Clinical Oncology Program, Columbus. Ohio, USA Summary Background Docetaxel and gemcitabine are active against breast cancer. The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c77fa46eb196f4f8872a3b411add6a
https://pubmed.ncbi.nlm.nih.gov/11697837
https://pubmed.ncbi.nlm.nih.gov/11697837
Autor:
R. Roach, L. Carman, Ch. George, R. Rupert, L. R. Laufman, J.Ph. Kuebler, C. H. Spiridonidis, T. Patel, Timothy Moore, J. Jones, S. Blair, D. Colborn, J. Zangmeister
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(1)
Summary Background Docetaxel and gemcitabine are active against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined with weekly gemcitabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5788d7eb57baaae53528203082876c3b
https://pubmed.ncbi.nlm.nih.gov/11249055
https://pubmed.ncbi.nlm.nih.gov/11249055
Autor:
N A, Rizvi, C H, Spiridonidis, T H, Davis, P, Bhargava, J L, Marshall, W, Dahut, M, Figuera, M J, Hawkins
Publikováno v:
Seminars in oncology. 26(5 Suppl 16)
Docetaxel and gemcitabine have been shown to be active as single agents in a variety of solid tumors. These two agents have been studied in combination with several different treatment schedules. Two phase I studies used a novel 2-week administration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ece1e9c63afab4a642c33b47cdefef9
https://pubmed.ncbi.nlm.nih.gov/10585006
https://pubmed.ncbi.nlm.nih.gov/10585006
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 16(12)
PURPOSE To determine the maximum-tolerated dose of monthly docetaxel combined with fixed-dose weekly gemcitabine and describe the dose-limiting toxicities (DLTs) of the combination. PATIENTS AND METHODS Patients with refractory solid tumors were trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dba7f89c8ed02d19b378cdcc7499feed
https://pubmed.ncbi.nlm.nih.gov/9850032
https://pubmed.ncbi.nlm.nih.gov/9850032
Publikováno v:
Cancer. 78(10)
In patients with advanced esophageal adenocarcinoma, the efficacy and palliative role of systemic chemotherapy are not well defined. The primary objective of this Phase II trial was to evaluate the antitumor activity and toxicity of a multiday chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63af60c51992c3272e71792ac1067243
https://pubmed.ncbi.nlm.nih.gov/8918399
https://pubmed.ncbi.nlm.nih.gov/8918399
Autor:
J Hohneker, J H Schiller, A Koletsky, M O'Rourke, C H Spiridonitis, Ralph W deVere White, C H Spiridonidis, L Hutchins, H Ozer, S Yanovich, A Langleben, S Burman, Jeffrey Crawford, G Clamon
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(10)
PURPOSE This prospective randomized trial was performed to compare the effectiveness of intravenous vinorelbine tartrate with intravenous fluorouracil and leucovorin (5-FU/LV) on the primary end points of survival, quality of life (QOL), and relief o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf44361a1751f33e3013956f430f3ef5
https://pubmed.ncbi.nlm.nih.gov/8874320
https://pubmed.ncbi.nlm.nih.gov/8874320